NCT00842127View on ClinicalTrials.gov

Genetic Polymorphism and OROS-Methylphenidate Treatment in Attention Deficit Hyperactivity Disorder(ADHD)

PHASE4CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions
Attention Deficit Hyperactivity Disorder
Interventions
DRUG

OROS-methylphenidate (Concerta)

dose: 18mg, 27mg, 36mg, 45mg, 54mg/day, po duration: 8 weeks

Trial Locations (1)

463-712

Bundang CHA hospital, Seongnam

All Listed Sponsors
collaborator

Hallym University Medical Center

OTHER

lead

Bundang CHA Hospital

OTHER

NCT00842127 - Genetic Polymorphism and OROS-Methylphenidate Treatment in Attention Deficit Hyperactivity Disorder(ADHD) | Biotech Hunter | Biotech Hunter